Cinolazepam
| Cinolazepam | |
|---|---|
| Molecular structure drawn from PubChem coordinates |
| Rotamer [] | |
|---|---|
| Conformer structure via 3Dmol.js |
| Physical properties [] | |
|---|---|
| Molecular mass | 357.80 g/mol [1] |
| Solubility | 1.20e-02 g/L [1] |
| Predicted LogP | 2 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C18H13ClFN3O2 |
| IUPAC name | 3-[7-chloro-5-(2-fluorophenyl)-3-hydroxy-2-oxo-3H-1,4-benzodiazepin-1-yl]propanenitrile |
| SMILES | C1=CC=C(C(=C1)C2=NC(C(=O)N(C3=C2C=C(C=C3)Cl)CCC#N)O)F |
| InChI | InChI=1S/C18H13ClFN3O2/c19-11-6-7-15-13(10-11)16(12-4-1-2-5-14(12)20)22-17(24)18(25)23(15)9-3-8-21/h1-2,4-7,10,17,24H,3,9H2 |
| InChIKey | XAXMYHMKTCNRRZ-UHFFFAOYSA-N |
| CAS number | 75696-02-5 |
| UNII | 68P0556B0U |
| PubChem CID | 3033621 |
| Pharmacokinetics[] | |
|---|---|
| Onset | 30 minutes to 1 hour |
| Elimination half-life | 9 hours |
| Duration of action | 9 hours |
| Metabolism | Hepatic |
| Excretion | Renal |
| Routes of administration | Oral |
| Dependence liability | High |
| Addiction liability | Medium |
Cinolazepam (also known as Gerodorm, Cinolazepamum, N05cd13, 687-760-2, Ox-373, Gerodorm; OX 373, C18H13ClFN3O2, Gerodorm (TN), Ox 373 or Brn 5359831) is a substance of the aniline and benzodiazepine class.
Chemistry
Stereochemistry []
Cinolazepam is a racemic mixture of the enantiomers (optical activity ( + / - )).
Druglikeness
Lipinski's rule of five
Cinolazepam matches Lipinski's rule of five.Pharmacology
ATC Classification
- nervous system (N)
- psycholeptics (N05)
- hypnotics and sedatives (N05C)
- benzodiazepine derivatives (N05CD)
- cinolazepam (N05CD13)
Mechanism of action []
Cinolazepam binds to central benzodiazepine receptors which interact allosterically with GABA receptors. This potentiates the effects of the inhibitory neurotransmitter GABA, increasing the inhibition of the ascending reticular activating system and blocking the cortical and limbic arousal that occurs following stimulation of the reticular pathways. [1]
Interactions []
Interaction mechanisms documented in KEGG DRUG (number of interacting drugs):
| GABRA1 | shared target | 5 |
|---|---|---|
| GABRA2 | shared target | 5 |
| GABRA3 | shared target | 5 |
| GABRA4 | shared target | 5 |
| GABRA5 | shared target | 5 |
| GABRA6 | shared target | 5 |
| GABRB1 | shared target | 5 |
| GABRB2 | shared target | 5 |
| GABRB3 | shared target | 5 |
| GABRD | shared target | 5 |
| GABRE | shared target | 5 |
| GABRG1 | shared target | 5 |
| GABRG2 | shared target | 5 |
| GABRG3 | shared target | 5 |
| GABRP | shared target | 5 |
| GABRQ | shared target | 5 |
Legal status []
- European Union: Cinolazepam is Prescription drug.
- United States: Cinolazepam is Unscheduled.
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 3033621, Cinolazepam. Accessed November 22, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/3033621
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Cinolazepam. UNII: 68P0556B0U. Global Substance Registration System. Accessed November 22, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/68P0556B0U
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 18:00:05 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 18:00:01 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 18:00:01 |
| gsrs | ok | 2026-11-20 18:00:01 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0015533) | 2026-11-20 18:00:01 |
| kegg | ok | 2026-11-20 18:00:03 |
| pubchem | ok | 2026-11-20 18:00:00 |
| missing (no r/tripreports posts mention it) | 2026-11-20 18:00:01 | |
| sider | missing (not in SIDER) | 2026-11-20 18:00:01 |
| structure | ok | 2026-11-20 18:00:01 |
| wikipedia | ok | 2026-11-20 18:00:01 |